Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S420 of response; complete response rate; progression-free, relapse-free, and overall survival; Lonca concentrations; and antidrug antibody titers. Key eligibility criteria: age ≥18 years, pathologic diagnosis of R/R B-NHL (2016 WHO classification), measurable disease (2014 Lugano classification), Tx failure/intolerance, ≥2 lines of prior therapy (LOT) for part 1 (≥1 LOT for part 2), and ECOG performance status of 0–2. Pts previously receiving a study drug are excluded from that respective arm. Status: Study opened: June 2022. As of March 2023: 17 pts enrolled with 12 treated in the Lonca + Pola arm. © 2023 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2023 ASCO Annual Meeting. All rights reserved. Funding: ADC Therapeutics SA; medical writing: CiTRUS Health Group. Keywords: non-Hodgkin lymphoma, loncastuximab tesirine, polatuzumab vedotin, glofitamab, mosunetuzumab, trialin-progress ABCL-142 Efficacy and Safety of Single‑Agent Blinatumomab as Salvage Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (B‑ALL): Real‑Life Experience İbrahim Halil Açar MD, Birol Güvenç MD Çukurova University Faculty of Medicine, Department of Haematology, Adana, Turkey Background and Objectives: Despite improved survival rates in adult B-ALL, many challenges remain in the management of patients with relapsed/refractory (r/r) B-ALL. Targeted therapies have been developed to overcome this challenge in r/r B-ALL. Blinatumomab, a bispecific anti-CD19/CD3 antibody, has demonstrated promising efficacy in the treatment of r/r B-ALL patients. This study aimed to evaluate the outcomes of blinatumomab treatment in adult patients with r/r B-ALL at a single center. Materials and Methods: In this retrospective, single-center, observational study, we included 34 adult patients with r/r B-ALL between 2019 and 2021 treated with blinatumomab. Treatment response, overall survival (OS), minimal residual disease (MRD), and feasibility of allogeneic hematopoietic stem cell transplantation (allo-HSCT) were assessed. Prognostic factors associated with treatment response and survival were also identified. Results: Patients received an average of 1 (1–3) cycles of blinatumomab treatment. No adverse events occurred in 79.4% of patients (n=27), while 20.6% (n=7) experienced various adverse events. Among these, 11.8% (n=4) were cytokine release syndrome, 5.9% (n=2) neurotoxicity, and 2.9% (n=1) neutropenia. The overall response rate was 64.7% (n=22), with a complete response rate of 44.1% (n=15). MRD negativity was achieved in 44.1% (n=15) of patients. Allo-HSCT was performed in 50% (n=17) of patients. Median follow-up time after blinatumomab treatment was 5.5 months (range: 1–40 months), median OS was 10 months (95% CI: range 3–17 months) and 3-year survival rate was 36%. Factors associated with increased mortality included hepatosplenomegaly, lymphadenopathy, high lactate dehydrogenase levels, high peripheral blood blast rate, and previous central nervous system involvement. Allo-HSCT after blinatumomab treatment was a factor associated with reduced mortality risk. Conclusion: Single-agent blinatumomab is a safe and effective treatment as salvage therapy in r/r B-ALL patients with poor prognostic features. Our findings support the effectiveness and safety of blinatumomab in adult patients with r/r B-ALL in a single-center real-world setting. The identification of prognostic factors can help guide treatment decisions and optimize patient outcomes. Keywords: blinatumomab, acute lymphoblastic leukemia, ALL, relapsed, refractory, single-center experience ABCL-152 Evaluation of Safety Profile of Rituximab + Lenalidomide Protocol in Frail Elderly Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Patients Bahar Sevgili MD1, Tural Pashayev MD2, Denis Sabriye Bozer MD1, Ajda Güneş MD1, Fatma Keklik Karacadağ MD3, Güray Saydam MD1 1Ege University, Faculty of Medicine, Department of Hematology, Izmir, Turkey. 2Liv Bona Dea Hospital, Department of Hematology, Baku, Azerbaijan. 3Tepecik Research and Education Hospital, Department of Hematology, Istanbul, Turkey Context: The standard treatment for frail elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) has not been established. Chemotherapy-free regimens such as rituximab + lenalidomide (R2) have shown promising results with an acceptable toxicity profile. This study aimed to evaluate the safety and adverse effects of the R2 protocol in elderly DLBCL patients. Case Report: Five elderly patients with R/R DLBCL who were ineligible for autologous stem cell transplantation were included in the study. Patient characteristics, such as age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), and Cumulative Illness Rating Scale-Geriatric (CIRS-G) scores, were recorded. The R2 protocol consisted of rituximab 375 mg/m2 on Day 1 and lenalidomide 5 to 20 mg on Days 1 to 21 for 6 cycles. Safety assessments included monitoring for cytopenias, infectious complications, and gastrointestinal or skin reactions. Response assessment was performed using positron emission tomography/ computed tomography based on Lugano criteria. The median follow-up after the first relapse was 14 months (range: 2-22 months). Results: Response assessment could not be performed for two patients due to treatment discontinuation or patient unavailability. Three patients had stage 4B DLBCL, one had stage 2B, and one had stage 1B. Three patients had extranodal involvement. The median CIRS-G score was 15 points, and the ECOG PS was 2. Lenalidomide dose reduction was required for three patients due to grade 3 cytopenias. Two patients experienced community-acquired pneumonia, and one had a urinary tract infection, all managed as outpatients. One patient experienced gastrointestinal side effects. No thromboembolic events were reported. Two of five patients achieved a partial response (PR), while two patients were refractory to the R2 protocol. One patient experienced early relapse after a PR, and two patients died of progressive disease. Conclusion: Managing R/R
RkJQdWJsaXNoZXIy MTk3NTQxMg==